Biogen Idec Inc (BIIB) 281.16 $BIIB
Why Sangamo BioSciences Shares Rose 26% in October
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:43AM CST
What: Shares of Sangamo BioSciences , a clinical-stage biotech focused on genomic editing, were up more than 26% in the month of October, according to data from S&P Capital IQ . So what: The company reported its third-quarter results...
BIIB: 281.16 (-2.37), SHPG: 211.27 (+4.26), SGMO: 7.23 (-0.02)
These Biotech Stocks May Start Paying Dividends in 2016
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 16, 12:43PM CST
Image source: Pictures of Money via Flickr. It's no secret that dividend stocks are the foundation on which great retirement portfolios are built. Dividend payments not only provide a hedge that can help offset the downside an investor may...
BIIB: 281.16 (-2.37), JAZZ: 141.58 (+4.20), ALXN: 170.39 (+1.48)
Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
at The Street - Mon Nov 16, 11:20AM CST
The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.
BLUE: 81.67 (+7.22), ZFGN: 14.64 (-0.08), BIIB: 281.16 (-2.37), VRX: 71.55 (-1.77), CLVS: 27.57 (-2.67), AZN: 33.27 (+0.49), FOLD: 9.39 (-0.74), CELG: 111.02 (+0.88)
A Pro Forma Profit for ISIS Pharmaceuticals, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Sun Nov 15, 5:00PM CST
Isis Pharmaceuticals reported earnings on Monday, and while the company does have a drug on the market, the focus is still entirely on the pipeline. Isis Pharmaceuticals results: The raw numbers Metric Q3 2015 Actuals Q3 2014...
BIIB: 281.16 (-2.37), ISIS: 60.92 (+0.65)
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 2.23% Sell Off
Comtex SmarTrend(R) - Fri Nov 13, 4:24PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $283.83 to a high of $293.29. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $290.91 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 281.16 (-2.37)
Biogen Idec Rises 1.30% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 281.16 (-2.37)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.30% Gain
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 281.16 (-2.37)
Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription
at The Street - Tue Nov 10, 6:05AM CST
Amgen's dividend may be just on par with the S&P 500's average, but its forward earnings ratio and price target make it a solid buy-and-hold candidate.
BIIB: 281.16 (-2.37), XBI: 68.69 (+0.54), ALXN: 170.39 (+1.48), AMGN: 157.91 (+3.41)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 281.16 (-2.37), GILD: 104.18 (+0.37), AMGN: 157.91 (+3.41), IBB: 329.01 (+4.12), REGN: 568.71 (+10.33), CELG: 111.02 (+0.88)
Anavex Presents Meaningless Results in Alzheimer's Drug Study
at The Street - Mon Nov 09, 7:53AM CST
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, a researcher who reviewed the data.
BIIB: 281.16 (-2.37), AVXL: 3.66 (-0.56)
$5.9 Billion Buyout: 1 Number Underpins Shire's Huge Dyax Bet
Michael Douglass, The Motley Fool - Motley Fool - Sat Nov 07, 6:42AM CST
The number, by the way, is $2 billion. That's how much Shire plc executives think Dyax Corporation 's flagship drug DX-2930 could provide in sales at its peak. If DX-2930 provides $2 billion in peak annual sales, then suddenly Shire's pricey...
BIIB: 281.16 (-2.37), SHPG: 211.27 (+4.26), LLY: 81.59 (+0.36), DYAX: 34.19 (-0.03)
Jim Cramer Loves Bank of America After Friday's Jobs Report
at The Street - Fri Nov 06, 5:01PM CST
Jim Cramer wants to add more Bank of America to the Action Alerts PLUS Portfolio on a pullback.
AGN: 297.72 (-0.99), UA: 85.29 (-4.71), MMM: 157.54 (-0.67), BIIB: 281.16 (-2.37), RCL: 94.82 (+0.46), FEYE: 21.97 (-0.50), CCL: 50.81 (+0.04), FB: 105.52 (+1.48), VFC: 61.91 (-0.85), KHC: 71.54 (-0.11), COLM: 46.55 (-3.25), BAC: 17.47 (+0.04), TWTR: 25.27 (-0.14), MS: 33.84 (-0.21)
Gilead and 2 Biotech Picks Value Investors Will Love
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 4:07PM CST
Don't miss these value biotech stocks for your portfolio.
BIIB: 281.16 (-2.37), ESRX: 84.04 (-0.62), GILD: 104.18 (+0.37), SHPG: 211.27 (+4.26), UTHR: 148.30 (+2.31), AMGN: 157.91 (+3.41), ANIK: 41.55 (-0.28)
Biotech Sees Better-than-Expected Earnings: ETFs in Focus
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 10:22AM CST
Driven by better-than-expected results, ETFs having considerable exposure to these five biotech companies have been surging.
BIIB: 281.16 (-2.37), GILD: 104.18 (+0.37), ALXN: 170.39 (+1.48), BBH: 123.47 (+1.50), IBB: 329.01 (+4.12), AMGN: 157.91 (+3.41), CELG: 111.02 (+0.88)
Stock Market News for November 06, 2015
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 9:10AM CST
Benchmarks closed modestly lower on Thursday as investors refrained from making big bets ahead of Friday’s nonfarm payroll report
KMI: 23.32 (-0.71), BIIB: 281.16 (-2.37), PCG: 52.49 (-0.95), FB: 105.52 (+1.48), XOM: 80.50 (-0.40), COP: 54.10 (-0.27), AMGN: 157.91 (+3.41), RL: 118.79 (-1.85), SO: 44.33 (-0.41), CELG: 111.02 (+0.88), AEP: 55.50 (-0.71), NEE: 101.67 (-0.45), GILD: 104.18 (+0.37), CVX: 91.46 (+0.01), OXY: 74.61 (-0.36)
Jim Cramer's 'Mad Money' Recap: Why You Should Sink Your Teeth Into FANG
at The Street - Thu Nov 05, 6:48PM CST
Cramer said Facebook, Amazon, Netflix and Alphabet -- the former Google -- represent the best of the best.
WFM: 29.93 (-0.14), MMM: 157.54 (-0.67), BIIB: 281.16 (-2.37), AMZN: 646.51 (-1.30), LMT: 223.24 (+2.57), FEYE: 21.97 (-0.50), GBX: 32.64 (-0.69), FB: 105.52 (+1.48), AGNC: 17.94 (+0.03), DIS: 116.71 (+0.79), PYPL: 36.22 (+0.61), BMY: 65.81 (+0.79), NFLX: 117.23 (+5.88), IRDM: 7.62 (+0.04), AA: 8.30 (+0.01), GILD: 104.18 (+0.37), BOOT: 9.30 (-0.57), NAT: 14.99 (-0.41), GOOGL: 751.74 (+1.32), TWTR: 25.27 (-0.14), PPG: 102.04 (+0.09)
Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 3:20PM CST
Isis Pharmaceuticals (ISIS), which is scheduled to report third-quarter 2015 results on Nov 9, had reported a negative earnings surprise of 14.71% last quarter.
MACK: 8.44 (-0.14), BIIB: 281.16 (-2.37), ISIS: 60.95 (+0.68), AZN: 33.27 (+0.49)
Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax
Arpita Dutt - Zacks Investment Research - Wed Nov 04, 9:41AM CST
Several major biotech companies including AbbVie (ABBV) reported their third quarter results over the last week.
BIIB: 281.16 (-2.37), GILD: 104.18 (+0.37), RPRX: 1.60 (+0.03), AMGN: 157.91 (+3.41), ABBV: 60.71 (+0.70), DYAX: 34.22 (unch), CELG: 111.07 (+0.93)
Why Sangamo BioSciences Shares Rose 26% in October
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:43AM CST
What: Shares of Sangamo BioSciences , a clinical-stage biotech focused on genomic editing, were up more than 26% in the month of October, according to data from S&P Capital IQ . So what: The company reported its third-quarter results...
BIIB: 281.16 (-2.37), SHPG: 211.27 (+4.26), SGMO: 7.23 (-0.02)
These Biotech Stocks May Start Paying Dividends in 2016
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 16, 12:43PM CST
Image source: Pictures of Money via Flickr. It's no secret that dividend stocks are the foundation on which great retirement portfolios are built. Dividend payments not only provide a hedge that can help offset the downside an investor may...
BIIB: 281.16 (-2.37), JAZZ: 141.58 (+4.20), ALXN: 170.39 (+1.48)
Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
at The Street - Mon Nov 16, 11:20AM CST
The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.
BLUE: 81.67 (+7.22), ZFGN: 14.64 (-0.08), BIIB: 281.16 (-2.37), VRX: 71.55 (-1.77), CLVS: 27.57 (-2.67), AZN: 33.27 (+0.49), FOLD: 9.39 (-0.74), CELG: 111.02 (+0.88)
A Pro Forma Profit for ISIS Pharmaceuticals, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Sun Nov 15, 5:00PM CST
Isis Pharmaceuticals reported earnings on Monday, and while the company does have a drug on the market, the focus is still entirely on the pipeline. Isis Pharmaceuticals results: The raw numbers Metric Q3 2015 Actuals Q3 2014...
BIIB: 281.16 (-2.37), ISIS: 60.92 (+0.65)
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 2.23% Sell Off
Comtex SmarTrend(R) - Fri Nov 13, 4:24PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $283.83 to a high of $293.29. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $290.91 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 281.16 (-2.37)
Biogen Idec Rises 1.30% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 281.16 (-2.37)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.30% Gain
Comtex SmarTrend(R) - Tue Nov 10, 3:47PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $291.23 to a high of $298.98. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $298.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 281.16 (-2.37)
Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription
at The Street - Tue Nov 10, 6:05AM CST
Amgen's dividend may be just on par with the S&P 500's average, but its forward earnings ratio and price target make it a solid buy-and-hold candidate.
BIIB: 281.16 (-2.37), XBI: 68.69 (+0.54), ALXN: 170.39 (+1.48), AMGN: 157.91 (+3.41)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 281.16 (-2.37), GILD: 104.18 (+0.37), AMGN: 157.91 (+3.41), IBB: 329.01 (+4.12), REGN: 568.71 (+10.33), CELG: 111.02 (+0.88)
Anavex Presents Meaningless Results in Alzheimer's Drug Study
at The Street - Mon Nov 09, 7:53AM CST
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, a researcher who reviewed the data.
BIIB: 281.16 (-2.37), AVXL: 3.66 (-0.56)
$5.9 Billion Buyout: 1 Number Underpins Shire's Huge Dyax Bet
Michael Douglass, The Motley Fool - Motley Fool - Sat Nov 07, 6:42AM CST
The number, by the way, is $2 billion. That's how much Shire plc executives think Dyax Corporation 's flagship drug DX-2930 could provide in sales at its peak. If DX-2930 provides $2 billion in peak annual sales, then suddenly Shire's pricey...
BIIB: 281.16 (-2.37), SHPG: 211.27 (+4.26), LLY: 81.59 (+0.36), DYAX: 34.19 (-0.03)
Jim Cramer Loves Bank of America After Friday's Jobs Report
at The Street - Fri Nov 06, 5:01PM CST
Jim Cramer wants to add more Bank of America to the Action Alerts PLUS Portfolio on a pullback.
AGN: 297.72 (-0.99), UA: 85.29 (-4.71), MMM: 157.54 (-0.67), BIIB: 281.16 (-2.37), RCL: 94.82 (+0.46), FEYE: 21.97 (-0.50), CCL: 50.81 (+0.04), FB: 105.52 (+1.48), VFC: 61.91 (-0.85), KHC: 71.54 (-0.11), COLM: 46.55 (-3.25), BAC: 17.47 (+0.04), TWTR: 25.27 (-0.14), MS: 33.84 (-0.21)
Gilead and 2 Biotech Picks Value Investors Will Love
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 4:07PM CST
Don't miss these value biotech stocks for your portfolio.
BIIB: 281.16 (-2.37), ESRX: 84.04 (-0.62), GILD: 104.18 (+0.37), SHPG: 211.27 (+4.26), UTHR: 148.30 (+2.31), AMGN: 157.91 (+3.41), ANIK: 41.55 (-0.28)
Biotech Sees Better-than-Expected Earnings: ETFs in Focus
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 10:22AM CST
Driven by better-than-expected results, ETFs having considerable exposure to these five biotech companies have been surging.
BIIB: 281.16 (-2.37), GILD: 104.18 (+0.37), ALXN: 170.39 (+1.48), BBH: 123.47 (+1.50), IBB: 329.01 (+4.12), AMGN: 157.91 (+3.41), CELG: 111.02 (+0.88)
Stock Market News for November 06, 2015
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 9:10AM CST
Benchmarks closed modestly lower on Thursday as investors refrained from making big bets ahead of Friday’s nonfarm payroll report
KMI: 23.32 (-0.71), BIIB: 281.16 (-2.37), PCG: 52.49 (-0.95), FB: 105.52 (+1.48), XOM: 80.50 (-0.40), COP: 54.10 (-0.27), AMGN: 157.91 (+3.41), RL: 118.79 (-1.85), SO: 44.33 (-0.41), CELG: 111.02 (+0.88), AEP: 55.50 (-0.71), NEE: 101.67 (-0.45), GILD: 104.18 (+0.37), CVX: 91.46 (+0.01), OXY: 74.61 (-0.36)
Jim Cramer's 'Mad Money' Recap: Why You Should Sink Your Teeth Into FANG
at The Street - Thu Nov 05, 6:48PM CST
Cramer said Facebook, Amazon, Netflix and Alphabet -- the former Google -- represent the best of the best.
WFM: 29.93 (-0.14), MMM: 157.54 (-0.67), BIIB: 281.16 (-2.37), AMZN: 646.51 (-1.30), LMT: 223.24 (+2.57), FEYE: 21.97 (-0.50), GBX: 32.64 (-0.69), FB: 105.52 (+1.48), AGNC: 17.94 (+0.03), DIS: 116.71 (+0.79), PYPL: 36.22 (+0.61), BMY: 65.81 (+0.79), NFLX: 117.23 (+5.88), IRDM: 7.62 (+0.04), AA: 8.30 (+0.01), GILD: 104.18 (+0.37), BOOT: 9.30 (-0.57), NAT: 14.99 (-0.41), GOOGL: 751.74 (+1.32), TWTR: 25.27 (-0.14), PPG: 102.04 (+0.09)
Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 3:20PM CST
Isis Pharmaceuticals (ISIS), which is scheduled to report third-quarter 2015 results on Nov 9, had reported a negative earnings surprise of 14.71% last quarter.
MACK: 8.44 (-0.14), BIIB: 281.16 (-2.37), ISIS: 60.95 (+0.68), AZN: 33.27 (+0.49)
Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax
Arpita Dutt - Zacks Investment Research - Wed Nov 04, 9:41AM CST
Several major biotech companies including AbbVie (ABBV) reported their third quarter results over the last week.
BIIB: 281.16 (-2.37), GILD: 104.18 (+0.37), RPRX: 1.60 (+0.03), AMGN: 157.91 (+3.41), ABBV: 60.71 (+0.70), DYAX: 34.22 (unch), CELG: 111.07 (+0.93)
